FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555631417> ?p ?o ?g. }

• W2555631417 endingPage "15923" @default.
• W2555631417 startingPage "15912" @default.
• W2555631417 abstract "Folate binding protein(FBP) is an immunogenic protein over-expressed in endometrial(EC) and ovarian cancer(OC). We are conducting a phase I/IIa trial of E39 (GALE 301)+GM-CSF, an HLA-A2-restricted, FBP-derived peptide vaccine to prevent recurrences in disease-free EC and OC patients. This interim analysis summarizes toxicity, immunologic responses, and clinical outcomes to date.HLA-A2+ patients were vaccinated(VG), and HLA-A2- or -A2+ patients were followed as controls(CG). Six monthly intradermal inoculations of E39+250mcg GM-CSF were administered to VG. Demographic, safety, immunologic, and recurrence rate(RR) data were collected and evaluated.This trial enrolled 51 patients; 29 in the VG and 22 in the CG. Fifteen patients received 1000mcg E39, and 14 received <1000mcg. There were no clinicopathologic differences between groups(all p ≥ 0.1). E39 was well-tolerated regardless of dose. DTH increased pre- to post-vaccination (5.7±1.5 mm vs 10.3±3.0 mm, p = 0.06) in the VG, and increased more in the 1000mcg group (3.8±2.0 mm vs 9.5±3.5 mm, p = 0.03). With 12 months median follow-up, the RR was 41% (VG) vs 55% (CG), p = 0.41. Among the 1000mcg patients, the RR was 13.3% vs 55% CG, p = 0.01. Estimated 2-year DFS was 85.7% in the 1000mcg group vs 33.6% in the CG (p = 0.021).This phase I/IIa trial reveals that E39+GM-CSF is well-tolerated and elicits a strong, dose-dependent in vivo immune response. Early efficacy results are promising in the 1000 mcg dose cohort. This study proves the safety and establishes the dose of E39 for a larger prospective, randomized, controlled trial in HLA-A2+ EC and OC patients to prevent recurrence." @default.
• W2555631417 created "2016-11-30" @default.
• W2555631417 creator A5010088272 @default.
• W2555631417 creator A5021690080 @default.
• W2555631417 creator A5023189770 @default.
• W2555631417 creator A5034838741 @default.
• W2555631417 creator A5035547335 @default.
• W2555631417 creator A5042613508 @default.
• W2555631417 creator A5044161354 @default.
• W2555631417 creator A5044899007 @default.
• W2555631417 creator A5050537038 @default.
• W2555631417 creator A5061745540 @default.
• W2555631417 creator A5064014389 @default.
• W2555631417 creator A5065391640 @default.
• W2555631417 creator A5074845988 @default.
• W2555631417 creator A5080595928 @default.
• W2555631417 creator A5081216998 @default.
• W2555631417 creator A5085457452 @default.
• W2555631417 creator A5086728731 @default.
• W2555631417 creator A5089299085 @default.
• W2555631417 date "2016-11-11" @default.
• W2555631417 modified "2023-09-30" @default.
• W2555631417 title "Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients" @default.
• W2555631417 cites W109931055 @default.
• W2555631417 cites W1862410697 @default.
• W2555631417 cites W1966775255 @default.
• W2555631417 cites W1970179806 @default.
• W2555631417 cites W1971341208 @default.
• W2555631417 cites W1976002760 @default.
• W2555631417 cites W1991228426 @default.
• W2555631417 cites W2014910913 @default.
• W2555631417 cites W2024132257 @default.
• W2555631417 cites W2024511800 @default.
• W2555631417 cites W2034669380 @default.
• W2555631417 cites W2063236751 @default.
• W2555631417 cites W2065949107 @default.
• W2555631417 cites W2077250280 @default.
• W2555631417 cites W2078140922 @default.
• W2555631417 cites W2079537409 @default.
• W2555631417 cites W2105678378 @default.
• W2555631417 cites W2108944797 @default.
• W2555631417 cites W2134175717 @default.
• W2555631417 cites W2155240407 @default.
• W2555631417 cites W2167129525 @default.
• W2555631417 cites W2307372011 @default.
• W2555631417 cites W2412663250 @default.
• W2555631417 cites W2419774672 @default.
• W2555631417 cites W2595875216 @default.
• W2555631417 cites W4232529261 @default.
• W2555631417 cites W4361867966 @default.
• W2555631417 doi "https://doi.org/10.18632/oncotarget.13305" @default.
• W2555631417 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5362533" @default.
• W2555631417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27852036" @default.
• W2555631417 hasPublicationYear "2016" @default.
• W2555631417 type Work @default.
• W2555631417 sameAs 2555631417 @default.
• W2555631417 citedByCount "8" @default.
• W2555631417 countsByYear W25556314172018 @default.
• W2555631417 countsByYear W25556314172019 @default.
• W2555631417 countsByYear W25556314172020 @default.
• W2555631417 countsByYear W25556314172021 @default.
• W2555631417 countsByYear W25556314172023 @default.
• W2555631417 crossrefType "journal-article" @default.
• W2555631417 hasAuthorship W2555631417A5010088272 @default.
• W2555631417 hasAuthorship W2555631417A5021690080 @default.
• W2555631417 hasAuthorship W2555631417A5023189770 @default.
• W2555631417 hasAuthorship W2555631417A5034838741 @default.
• W2555631417 hasAuthorship W2555631417A5035547335 @default.
• W2555631417 hasAuthorship W2555631417A5042613508 @default.
• W2555631417 hasAuthorship W2555631417A5044161354 @default.
• W2555631417 hasAuthorship W2555631417A5044899007 @default.
• W2555631417 hasAuthorship W2555631417A5050537038 @default.
• W2555631417 hasAuthorship W2555631417A5061745540 @default.
• W2555631417 hasAuthorship W2555631417A5064014389 @default.
• W2555631417 hasAuthorship W2555631417A5065391640 @default.
• W2555631417 hasAuthorship W2555631417A5074845988 @default.
• W2555631417 hasAuthorship W2555631417A5080595928 @default.
• W2555631417 hasAuthorship W2555631417A5081216998 @default.
• W2555631417 hasAuthorship W2555631417A5085457452 @default.
• W2555631417 hasAuthorship W2555631417A5086728731 @default.
• W2555631417 hasAuthorship W2555631417A5089299085 @default.
• W2555631417 hasBestOaLocation W25556314171 @default.
• W2555631417 hasConcept C121608353 @default.
• W2555631417 hasConcept C126322002 @default.
• W2555631417 hasConcept C143998085 @default.
• W2555631417 hasConcept C159654299 @default.
• W2555631417 hasConcept C195616568 @default.
• W2555631417 hasConcept C203014093 @default.
• W2555631417 hasConcept C2776789287 @default.
• W2555631417 hasConcept C2780427987 @default.
• W2555631417 hasConcept C535046627 @default.
• W2555631417 hasConcept C61943457 @default.
• W2555631417 hasConcept C71924100 @default.
• W2555631417 hasConcept C90924648 @default.
• W2555631417 hasConceptScore W2555631417C121608353 @default.
• W2555631417 hasConceptScore W2555631417C126322002 @default.
• W2555631417 hasConceptScore W2555631417C143998085 @default.
• W2555631417 hasConceptScore W2555631417C159654299 @default.

• next